In septic shock, what are the first‑, second‑, third‑, and fourth‑line vasopressors of choice, and what is the pathophysiology of septic shock?

Septic Shock: Vasopressor Selection and Pathophysiology

Vasopressor Algorithm

Norepinephrine is the first-line vasopressor for septic shock, targeting a MAP of 65 mmHg 1. This recommendation is based on strong evidence showing reduced mortality compared to dopamine, with fewer cardiac arrhythmias and adverse events 2.

First-Line Vasopressor

• Norepinephrine (Grade 1B, strong recommendation)
  • Start as soon as possible after fluid resuscitation begins
  • Target MAP ≥65 mmHg initially
  • Recent reinforcement learning data suggests earlier initiation (median 4 hours from shock onset) at lower doses (0.20 µg/kg/min) may improve outcomes 3
  • Dopamine is only acceptable in highly selected patients with low arrhythmia risk and absolute/relative bradycardia (Grade 2C) 1

Second-Line Vasopressors

When norepinephrine alone fails to achieve MAP targets, add vasopressin 0.03 units/minute 1. The guidelines frame this as either adding vasopressin OR epinephrine, but the evidence hierarchy favors vasopressin:

• Vasopressin 0.03 units/minute (weak recommendation, moderate quality evidence)

  • Add to norepinephrine to raise MAP or decrease norepinephrine dose
  • Do NOT use as single initial vasopressor
  • Do NOT exceed 0.03-0.04 units/minute except for salvage therapy 1

• Epinephrine (Grade 2B, weak recommendation, low quality evidence)

  • Alternative second-line option when additional agent needed
  • Can be added to or substituted for norepinephrine
  • Higher risk of metabolic and cardiac adverse effects compared to norepinephrine 4
  • May be preferred when myocardial dysfunction is present

Third-Line Options

If MAP targets remain unmet despite norepinephrine plus vasopressin (or epinephrine), escalate norepinephrine dosing up to ≥1 µg/kg/min 5. At this point, consider:

• High-dose vasopressin (>0.03-0.04 units/minute) as salvage therapy 1
• Phenylephrine only in specific circumstances (Grade 1C):
  • Norepinephrine causing serious arrhythmias
  • Cardiac output known to be high with persistently low BP
  • Salvage therapy when other combinations fail 1

Fourth-Line/Salvage Therapy

Phenylephrine is the fourth-line agent, reserved strictly for salvage situations when combined inotrope/vasopressor drugs and low-dose vasopressin have failed 6, 1. The guidelines explicitly recommend against phenylephrine except in the three specific circumstances listed above.

Critical Pitfalls to Avoid

• Never use low-dose dopamine for renal protection (Grade 1A) 1 - this is strongly contraindicated despite historical practice
• Avoid dopamine as first-line - it increases mortality and arrhythmias compared to norepinephrine 2
• Do not delay vasopressor initiation - early administration (within first hour) may reduce morbidity and mortality 7
• Do not use vasopressin as monotherapy - it should only be added to norepinephrine 1

Inotropic Support

Add dobutamine (up to 20 µg/kg/min) when myocardial dysfunction or persistent hypoperfusion exists despite adequate fluids and MAP (Grade 1C) 6. This is technically an adjunct rather than a vasopressor, but critical for patients with:

• Elevated cardiac filling pressures with low cardiac output
• Ongoing signs of hypoperfusion despite adequate volume and MAP

Pathophysiology of Septic Shock

Septic shock represents distributive shock characterized by:

Vascular Dysfunction:

• Profound vasodilation from inflammatory mediators (cytokines, nitric oxide, prostacyclin)
• Loss of vascular smooth muscle tone
• Decreased systemic vascular resistance
• Relative vasopressin deficiency in late septic shock

Myocardial Dysfunction:

• Sepsis-induced cardiomyopathy with decreased contractility
• Impaired response to catecholamines
• Elevated cardiac filling pressures despite reduced cardiac output

Microcirculatory Failure:

• Endothelial dysfunction and increased capillary permeability
• Maldistribution of blood flow
• Tissue hypoxia despite adequate macrocirculatory parameters

Metabolic Derangements:

• Lactic acidosis from tissue hypoperfusion and mitochondrial dysfunction
• Cellular oxygen utilization impairment

The rationale for norepinephrine as first-line therapy is its balanced α1-adrenergic (vasoconstriction) and β1-adrenergic (inotropy) effects, directly addressing the primary pathophysiologic defect of vasodilation while supporting cardiac function. Vasopressin works through V1 receptors, providing an alternative vasoconstriction pathway when catecholamine receptors are downregulated or desensitized 5, 4.

Evidence Quality Note

The 2016 Surviving Sepsis Campaign guidelines 1 represent the most recent comprehensive guideline evidence, superseding the 2012 guidelines 6. The vasopressor hierarchy remained consistent between versions, with norepinephrine maintaining its Grade 1B recommendation. Recent 2025 reinforcement learning data 3 suggests current practice may be too conservative with vasopressin timing, though this requires prospective validation before changing guideline recommendations.